Try our mobile app

Switch to company model in classical logic    *

General information

Country: FRANCE

Sector: Biotechnology

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company`s lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Website: biophytis.com




Profitability: LTM EBITDA margin is negative, 0.0%.

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.0% (LTM)

Entry Point: Share price is 3 248.3% higher than minimum and 36.8% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: BPTS
Share price, USD:  (0.0%)8.22
year average price 1.45  


year start price 3.33 2023-05-08

min close price 0.25 2024-04-22

max close price 10.19 2024-04-23

current price 8.22 2024-05-06
Common stocks: 1 132 885 340

Dividend Yield:  0.0%
Last revenue growth (y/y):  ---
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 9 312
Net Debt ($m): 4
EV (Enterprise Value): 9 316
Price to Book: -2 228.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-09Zacks Investment Research

Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up

2024-04-09InvestorPlace

Why Is Biophytis (BPTS) Stock Up 43% Today?

2023-09-26Zacks Investment Research

Biophytis (BPTS) Soars 73% on Partnership With Skyepharma

2023-09-25Proactive Investors

Biophytis shares surge 41% following Covid partnership with France's Skyepharma

2023-09-25InvestorPlace

Why Is Biophytis (BPTS) Stock Up 49% Today?

2023-09-04Accesswire

Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York

2023-08-08InvestorPlace

Why Is Biophytis (BPTS) Stock Up 18% Today?

2023-07-18MarketBeat

Russell 2000 ETF Momentum Sparks Volatility In Small Caps

2023-07-18InvestorPlace

Why Is Biophytis (BPTS) Stock Up 66% Today?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q2 2022 q4 2021 q4 2020 q4 2020 q2 2019 q2 2019 q1
date 2023-12-31 2023-06-30 2022-12-31 2021-12-31 2020-12-31 2020-06-30 2019-06-30 2019-03-31
symbol BPTS BPTS BPTS BPTS BPTS BPTS BPTS BPTS
reportedCurrency EUR EUR USD USD EUR EUR EUR EUR
cik 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-08 2023-06-30 2023-04-19 2022-04-21 2020-12-31 2020-06-30 2019-06-30 2019-03-31
acceptedDate 2024-04-08 17:02:38 2023-06-29 20:00:00 2023-04-18 19:19:56 2022-04-21 08:58:41 2020-12-31 2020-06-30 2019-06-30 00:00:00 2019-03-31 00:00:00
calendarYear 2023.000 2023.000 2022.000 2021.000 2020.000 2020.000 2019.000 2019.000
period Q4 Q2 Q4 Q4 Q4 Q2 Q2 Q1
revenue 0 0 0 0 0 0 0 0
costOfRevenue 653 000 150 000 334 000 0 0 0 0 0
grossProfit -653 000 -150 000 -334 000 0 0 0 0 0
grossProfitRatio 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 6M 5M 10M -7M 2M 3M 3M 2M
generalAndAdministrativeExpenses 2727.000 2761.000 2184.000 5M 876 000 1M 4M 1M
sellingAndMarketingExpenses 2M 3M 2M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2M 3M 2M -5M 0 0 4M 1M
otherExpenses 0 0 0 0 0 0 0 0
operatingExpenses 8M 7M 12M -12M 0 0 6M 4M
costAndExpenses 8M 7M 12M -12M 0 0 6M 4M
interestIncome 0 724.000 990 000 0 0 0 0 0
interestExpense 491 000 760 000 211 000 -597 000 -390 000 -1M 308 000 268 000
depreciationAndAmortization 653 000 150 000 334 000 -185 000 0 64 500 16 000 61 000
ebitda -8M -7M -12M 12M -4M -6M -6M -3M
ebitdaratio 0 0 0 0 0 0 0 0
operatingIncome -8M -7M -12M 12M -3M -4M -6M -4M
operatingIncomeRatio 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet -1M -1M -467 000 571 000 -556 500 -999 500 -354 000 1000.000
incomeBeforeTax -10M -9M -13M 13M -4M -5M -6M -4M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0
incomeTaxExpense -639 000 -922 000 -799 000 0 0 0 308 000 0
netIncome -9M -8M -12M 13M -4M -5M -7M -4M
netIncomeRatio 0 0 0 0 0 0 0 0
eps -0.009 -0.024 -0.055 2.770 -2.820 -3.513 0 -2.770
epsdiluted -0.009 -0.024 -0.055 2.770 -2.820 -3.513 0 -2.770
weightedAverageShsOut 1 040M 328M 216M 0 1M 1M 0 1M
weightedAverageShsOutDil 1 040M 328M 216M 0 1M 1M 0 1M
link Link Link Link
finalLink Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q2 2023 q1 2022 q4 2022 q2 2021 q4
date 2023-12-31 2023-06-30 2023-04-19 2022-12-31 2022-06-30 2021-12-31
symbol BPTS BPTS BPTS BPTS BPTS BPTS
reportedCurrency EUR EUR USD EUR EUR EUR
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-08 2023-06-30 2023-04-19 2023-04-19 2022-06-30 2021-12-31
acceptedDate 2024-04-08 17:02:38 2023-06-29 20:00:00 2023-04-19 10:46:03 2023-04-18 19:19:56 2022-06-30 00:00:00 2021-12-31 00:00:00
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2021.000
period Q4 Q2 Q1 Q4 Q2 Q4
cashAndCashEquivalents 6M 6M 0 11M 20M 24M
shortTermInvestments 368 000 432 000 0 590 000 407 000 1M
cashAndShortTermInvestments 6M 6M 0 12M 20M 25M
netReceivables 2M 5M 0 5M 8M 5M
inventory 0 152 000 0 2M 0 0
otherCurrentAssets 842 000 -2000.000 0 -1000.000 2M 1M
totalCurrentAssets 9M 11M 0 19M 30M 32M
propertyPlantEquipmentNet 315 000 425 000 0 584 000 717 000 563 000
goodwill 0 0 0 0 0 0
intangibleAssets 3M 3M 0 3M 3M 3M
goodwillAndIntangibleAssets 3M 3M 0 3M 3M 3M
longTermInvestments 134 000 164 000 0 47 000 49 000 82 000
taxAssets 1000.000 0 0 0 0 0
otherNonCurrentAssets -1000.000 1000.000 0 125 000 126 000 1M
totalNonCurrentAssets 3M 3M 0 3M 4M 5M
otherAssets -0.000 0 0 0 0 0
totalAssets 12M 15M 0 22M 34M 36M
accountPayables 5M 4M 0 7M 10M 8M
shortTermDebt 5M 6M 0 8M 10M 9M
taxPayables -44 000 65 000 0 94 000 59 000 2M
deferredRevenue 178 000 1M 0 178 000 178 000 175 000
otherCurrentLiabilities 2M 3M 0 4M 5M 6M
totalCurrentLiabilities 12M 14M 0 19M 26M 23M
longTermDebt 3M 3M 0 4M 4M 6M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 373 000 747 000 0 183 000 -15M 1M
totalNonCurrentLiabilities 3M 4M 0 5M 5M 7M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 136 000 333 000 0 470 000 604 000 446 000
totalLiabilities 16M 18M 0 24M 31M 31M
preferredStock 0 0 0 0 0 0
commonStock 2M 4M 0 48M 33M 27M
retainedEarnings -19M -16M 0 -48M -38M -49M
accumulatedOtherComprehensiveIncomeLoss -25 000 -7000.000 0 -25 000 -27 000 -73 000
othertotalStockholdersEquity 13M 8M 0 -2M 8M 28M
totalStockholdersEquity -4M -3M 0 -2M 3M 6M
totalEquity -4M -3M 0 -2M 3M 6M
totalLiabilitiesAndStockholdersEquity 12M 15M 0 22M 34M 36M
minorityInterest -32 000 -32 000 0 -32 000 0 0
totalLiabilitiesAndTotalEquity 12M 15M 0 22M 34M 36M
totalInvestments 134 000 596 000 0 637 000 456 000 1M
totalDebt 8M 10M 0 12M 14M 15M
netDebt 3M 4M 0 1M -5M -9M
link Link Link Link
finalLink Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q2 2022 q4 2021 q4 2020 q4 2020 q2 2019 q2 2019 q1
date 2023-12-31 2023-06-30 2022-12-31 2021-12-31 2020-12-31 2020-06-30 2019-06-30 2019-03-31
symbol BPTS BPTS BPTS BPTS BPTS BPTS BPTS BPTS
reportedCurrency EUR EUR USD USD EUR EUR EUR EUR
cik 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-08 2023-06-30 2023-04-19 2022-04-21 2020-12-31 2020-06-30 2019-06-30 2019-03-31
acceptedDate 2024-04-08 17:02:38 2023-06-29 20:00:00 2023-04-18 19:19:56 2022-04-21 08:58:41 2020-12-31 2020-06-30 2019-06-30 00:00:00 2019-03-31 00:00:00
calendarYear 2023.000 2023.000 2022.000 2021.000 2020.000 2020.000 2019.000 2019.000
period Q4 Q2 Q4 Q4 Q4 Q2 Q2 Q1
netIncome -9M -8M -12M -13M -4M -5M -6M -4M
depreciationAndAmortization 653 000 150 000 334 000 95 000 0 64 500 67 000 61 000
deferredIncomeTax 247 496 -2M -570 205 0 0 0 113 000 0
stockBasedCompensation 504.000 322.000 2205.000 616 000 0 0 9000.000 27 000
changeInWorkingCapital 2M -2M 631 000 2M 0 3M -3M 2M
accountsReceivables -348 000 2M 3M -3M 0 2M 0 0
inventory 0 1.000 0 0 0 0 0 0
accountsPayables 2M -3M -3M 818 000 0 0 -660 000 859 000
otherWorkingCapital 495 000 -863 000 531 000 4M 0 0 -2M 0
otherNonCashItems 1M 3M 3M 13M 4M 2M 4M 0
netCashProvidedByOperatingActivities -5M -8M -9M 3M 0 0 -5M -5M
investmentsInPropertyPlantAndEquipment -130 000 -90 000 -119 000 308 000 0 -500.000 -273 000 0
acquisitionsNet -1277.000 687.000 0 0 0 0 0 0
purchasesOfInvestments 695 000 -695 000 0 -13M 0 0 0 0
salesMaturitiesOfInvestments 582 000 8000.000 -341 000 0 0 0 0 0
otherInvestingActivites 1277.000 -687.000 110 000 -214 000 0 1000.000 3000.000 -13 000
netCashUsedForInvestingActivites 1M -777 000 -350 000 -12M 0 500.000 -270 000 -13 000
debtRepayment -330 000 -1M -386 000 -887 000 0 2M -677 000 -170 000
commonStockIssued 4M 2M -1000.000 0 0 0 0 0
commonStockRepurchased 0 0 -1.000 0 0 0 0 0
dividendsPaid 0 0 -243 999 0 0 0 0 0
otherFinancingActivites -1M 1M 1M 21M 0 688 000 297 000 2M
netCashUsedProvidedByFinancingActivities 4M 4M 420 000 20M 0 3M -380 000 2M
effectOfForexChangesOnCash 15.000 -24.000 -61.000 31 000 0 0 33 000 -49 000
netChangeInCash -215 000 -5M -9M 640 000 0 3M -6M -3M
cashAtEndOfPeriod 6M 6M 11M 6M 0 0 5M 11M
cashAtBeginningOfPeriod 6M 11M 20M 5M 0 0 11M 14M
operatingCashFlow -5M -8M -9M 3M 0 0 -5M -5M
capitalExpenditure -130 000 -90 000 -119 000 308 000 0 -500.000 -273 000 -14 000
freeCashFlow -5M -8M -9M 3M 0 0 -6M -5M
link Link Link Link
finalLink Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-04-04 21:00 ET
Results of the Combined General Meeting on April 2, 2024
2024-03-22 06:20 ET
Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia
2023-11-17 22:15 ET
Biophytis Announces Receipt of Nasdaq Notice
2023-10-30 05:20 ET
Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in Brazil
2023-10-27 21:00 ET
Biophytis Receives Notice of Delisting From Nasdaq and Announces It Will Request a Hearing Before the Nasdaq Hearings Panel
2023-09-27 21:45 ET
Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations
2023-09-25 05:30 ET
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)
2023-09-19 05:40 ET
Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
2023-09-14 05:30 ET
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer
2023-09-11 05:20 ET
Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia
2023-09-04 21:30 ET
Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York
2023-08-16 05:15 ET
Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project
2023-08-08 05:20 ET
Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe
2023-07-20 05:20 ET
Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19
2023-07-19 06:20 ET
Biophytis Announces $3.8 Million Registered Direct Offering
2023-07-18 05:20 ET
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound
2023-07-10 05:00 ET
Biophytis Has Filed with The FDA For Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia
2023-06-19 05:30 ET
Biophytis Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress
2023-06-16 21:20 ET
Biophytis: Results of the Annual General Meeting on June 16, 2023 All Resolutions Presented by the Company Have Been Adopted
2023-06-05 06:20 ET
Biophytis to Participate at the BIO International Convention in Boston from the 5th to the 8th of June
2023-05-26 06:30 ET
Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
2023-05-25 06:20 ET
Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference
2023-05-15 06:20 ET
Biophytis has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia
2023-05-11 06:20 ET
Successful Capital Increase for Biophytis with €2.3 million Raised
2023-05-10 18:10 ET
Biophytis Launches a Round of Fundraising for Approximately 2 Million Euros
2023-05-09 06:20 ET
Biophytis has Requested a Pre-Submission Meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the Treatment of COVID-19
2023-05-02 06:20 ET
Biophytis Strengthens its Management Team
2023-04-28 21:30 ET
Biophytis Announces Receipt of Nasdaq Notice
2023-04-19 06:20 ET
Biophytis Regains Compliance with NASDAQ Minimum Bid Price Requirement
2023-04-18 07:45 ET
Biophytis Announces 2022 Financial Results and 2023 Perspectives
2023-04-18 04:20 ET
Biophytis: Results of the Combined General Meeting on April 17, 2023
2023-03-30 21:20 ET
Biophytis: The Combined General Meeting Will Be Held on Second Call on April 17, 2023
2023-03-27 06:20 ET
Biophytis: Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate for Long COVID After Hospitalization During The 13th Annual International Conference on Frailty and Sarcopenia Resea
2023-03-17 07:20 ET
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
2023-03-09 07:20 ET
Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference
2023-03-02 07:00 ET
Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19
2023-02-27 07:20 ET
Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19
2023-02-23 07:20 ET
Biophytis To Host a Combined General Shareholder’s Meeting on March 30, 2023
2023-02-02 07:20 ET
Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19
2023-01-31 07:20 ET
Biophytis Publishes its Financial Results for the First Half of 2022
2023-01-19 07:00 ET
Biophytis: Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd
2023-01-12 07:20 ET
Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice
2023-01-05 07:20 ET
Biophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities Biomed
2022-12-01 07:30 ET
Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure
2022-11-03 07:20 ET
Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19
2022-10-31 23:10 ET
Biophytis Publishes Its Key Financial Figures As at 30 June 2022, Announces a Restatement of the Financial Statements Published As of December 31st, 2021 and Provides an Update on the Operational Milestones
2022-10-26 06:45 ET
Biophytis Announces Receipt of Nasdaq Notice
2022-09-15 06:30 ET
Biophytis Participates in H.C. Wainwright 24th Annual Global Investment Conference
2022-09-13 06:20 ET
The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd
2022-09-07 06:20 ET
Biophytis Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related Respiratory Failure
2022-06-30 21:20 ET
Biophytis Announces the Drawing of the Second Tranche of Ornane Under the 2021 Atlas Contract for €4 Million
2022-06-27 21:45 ET
Biophytis Presents the Development of Sarconeos (BIO101) in Phase 3 for the Treatment of Sarcopenia at the 15th SCWD International Congress
2022-06-22 21:30 ET
Biophytis: Results of the Combined General Meeting on June 21, 2022
2022-06-16 06:20 ET
Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a Rare Neuromuscular Disease
2022-06-03 21:20 ET
Biophytis: Convening of Another Combined General Meeting at a Later Date
2022-05-12 06:20 ET
Biophytis: Biophytis Announces its Participation at the BIO International Convention in San Diego from the 13th to the 16th of June
2022-04-19 06:20 ET
Biophytis: Biophytis Presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022
2022-04-07 06:25 ET
Biophytis Provides Updates on Sarconeos (BIO101) Clinical Development
2022-04-07 06:25 ET
Biophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives
2022-04-05 21:30 ET
Biophytis Appoints Philippe Rousseau as Chief Financial Officer
2022-03-16 07:20 ET
Biophytis will Participate in a Key Workshop on Functional Limitations for the Elderly
2022-02-03 08:00 ET
Biophytis Received Approval from ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients through an Expanded Access Program
2021-12-22 22:20 ET
Biophytis Announces the Drawing of the Last Tranche of ORNANE Under the 2020 Atlas Contract for €3 Million
2021-12-16 07:30 ET
Biophytis to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3
2021-11-22 22:20 ET
Biophytis Obtains a New 10M€ Loan Structure With Kreos Capital
2021-11-15 07:30 ET
Biophytis Announces US Centers to Restart Recruitment for the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19
2021-10-29 06:55 ET
Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021
2021-10-06 21:00 ET
Biophytis to Restate Previously Issued Financial Statements
2021-10-06 06:00 ET
Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its Lead Projects in COVID-19 and Sarcopenia
2021-10-04 21:00 ET
Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for €6 Million
2021-10-04 06:00 ET
Biophytis Announces Promising Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021
2021-09-29 06:00 ET
Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021
2021-09-17 06:00 ET
Biophytis Reports H1 2021 Financial Results and Provides Business Update
2021-09-15 06:00 ET
Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19
2021-09-14 06:00 ET
Biophytis to Attend Key Upcoming Investor Events and Industry Conferences
2021-09-09 06:00 ET
Biophytis Leadership is Reinforced With New Chief Medical Officer Appointment
2021-08-16 06:00 ET
Biophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC) Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the COVA Study in COVID-19
2021-08-13 21:00 ET
Biophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Reserved for NEGMA and the Performance of the Judgments of March 16, 2021 and July 16, 2021
2021-08-02 06:00 ET
Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia
2021-07-19 21:00 ET
Judgment Rendered on July 16, 2021 in the Proceedings Between Biophytis and Negma Group Ltd by the Execution Judge From the Paris Court of Justice
2021-07-12 06:00 ET
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
2021-07-08 06:00 ET
Biophytis Reinforces Leadership Teams with Three Senior Appointments
2021-06-30 21:00 ET
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021
2021-06-30 21:00 ET
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study
2021-06-19 00:00 ET
Biophytis announces new convertible bond financing for up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
2021-05-12 06:00 ET
BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis
2021-05-11 06:00 ET
BIOPHYTIS - Results of the Combined General Meeting on May 10, 2021
2021-04-30 06:00 ET
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
2021-04-29 06:00 ET
Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos (BIO201) in Dry AMD
2021-04-27 06:00 ET
Biophytis - Convening of Another Combined General Meeting at a Later Date
2021-04-26 06:00 ET
Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021
2021-04-13 21:00 ET
BIOPHYTIS Identifies False Report Regarding COVA study
2021-03-22 07:00 ET
BIOPHYTIS Gives Updates on its Phase 2-3 COVA Study on COVID-19
2021-03-19 22:00 ET
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis Against Negma Group Ltd
2021-03-11 03:08 ET
Biophytis’ Combined Annual General Meeting Will Take Place on April 26, 2021 behind closed doors
2021-02-26 07:00 ET
Biophytis Reports 2020 Full Year Results
2021-02-17 07:00 ET
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium
2021-02-15 07:00 ET
Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market
2021-02-10 14:16 ET
Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext Growth
2021-02-10 14:16 ET
Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext Growth
2021-02-10 09:40 ET
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market
2021-02-10 09:28 ET
Biophytis Announces Temporary Trading Halt of its Ordinary Shares and Share Warrants on Euronext Growth
2021-02-10 07:00 ET
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market
2021-02-10 07:00 ET
Biophytis Announces Temporary Trading Halt of its Ordinary Shares and Share Warrants on Euronext Growth
2021-02-03 07:00 ET
Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”)
2021-02-03 07:00 ET
Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing
2021-02-03 07:00 ET
Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”)
2021-02-03 07:00 ET
Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing

SEC forms

Show financial reports only

SEC form 6
2024-02-22 14:41 ET
Biophytis S.A. published news for 2023 q4
SEC form 6
2024-02-22 14:41 ET
Biophytis S.A. published news for 2023 q4
SEC form 6
2024-01-05 12:11 ET
Biophytis S.A. published news for 2023 q4
SEC form 6
2024-01-05 12:11 ET
Biophytis S.A. published news for 2023 q4
SEC form 6
2024-01-05 12:09 ET
Biophytis S.A. published news for 2023 q4
SEC form 6
2024-01-05 12:09 ET
Biophytis S.A. published news for 2023 q4
SEC form 6
2023-11-21 11:37 ET
Biophytis S.A. published news for 2023 q3
SEC form 6
2023-11-21 10:29 ET
Biophytis S.A. published news for 2023 q3
SEC form 6
2023-11-07 12:45 ET
Biophytis S.A. published news for 2023 q3
SEC form 6
2023-11-02 14:44 ET
Biophytis S.A. published news for 2023 q3
SEC form 6
2023-10-27 17:15 ET
Biophytis S.A. published news for 2023 q3
SEC form 6
2023-10-23 16:59 ET
Biophytis S.A. published news for 2023 q3
SEC form 6
2023-10-23 10:43 ET
Biophytis S.A. published news for 2023 q3
SEC form 6
2023-09-28 10:18 ET
Biophytis S.A. published news for 2023 q2
SEC form 6
2023-09-27 17:00 ET
Biophytis S.A. reported for 2023 q2
SEC form 6
2023-08-25 12:29 ET
Biophytis S.A. published news for 2023 q2
SEC form 6
2023-08-25 12:21 ET
Biophytis S.A. published news for 2023 q2
SEC form 6
2023-08-25 12:21 ET
Biophytis S.A. published news for 2023 q2
SEC form 6
2023-07-21 06:01 ET
Biophytis S.A. published news for 2023 q2
SEC form 6
2023-07-20 11:35 ET
Biophytis S.A. published news for 2023 q2
SEC form 6
2023-07-19 10:26 ET
Biophytis S.A. published news for 2023 q2
SEC form 6
2023-07-18 10:00 ET
Biophytis S.A. published news for 2023 q2
SEC form 6
2023-07-10 09:46 ET
Biophytis S.A. published news for 2023 q2
SEC form 6
2023-07-03 16:15 ET
Biophytis S.A. published news for 2023 q2
SEC form 6
2023-05-26 13:23 ET
Biophytis S.A. published news for 2023 q1
SEC form 6
2023-05-25 11:00 ET
Biophytis S.A. published news for 2023 q1
SEC form 6
2023-05-15 10:31 ET
Biophytis S.A. published news for 2023 q1
SEC form 6
2023-05-11 11:22 ET
Biophytis S.A. published news for 2023 q1
SEC form 6
2023-05-09 14:35 ET
Biophytis S.A. published news for 2023 q1
SEC form 6
2023-05-02 10:00 ET
Biophytis S.A. published news for 2023 q1
SEC form 6
2023-05-02 09:40 ET
Biophytis S.A. published news for 2023 q1
SEC form 6
2023-04-19 10:46 ET
Biophytis S.A. published news for 2023 q1
SEC form 6
2023-04-18 19:19 ET
Biophytis S.A. published news for 2023 q1
SEC form 6
2023-04-18 11:35 ET
Biophytis S.A. published news for 2023 q1
SEC form 6
2023-03-31 10:18 ET
Biophytis S.A. published news for 2022 q4
SEC form 6
2023-03-27 12:08 ET
Biophytis S.A. published news for 2022 q4